Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04971694 · ClinicalTrials.gov registry record

Impact of Steroid, Diuretic, and Fluid Use on BPD Outcomes

A clinical trial, sponsored by Pediatrix.

Completed
Registry status
175
Enrollment target

NCT04971694: Completed study, sponsored by Pediatrix.

NCT04971694 is a clinical trial that has completed, run by Pediatrix. The registered enrollment target is 175 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04971694 has completed, sponsored by Pediatrix.

COMPLETED
Registry status
175 participants
Enrollment target

Study Summary

Assess the impact of steroid, diuretic, and fluid practices on BPD outcomes in extreme premature infants in the Banner - University Medical Center Phoenix (BUMCP) neonatal intensive care unit (NICU).

Primary Outcome

\- The incidence of BPD stratified into three stages based on the type of support required at 36 weeks CGA

Interventions

  • OTHER No interventions or procedures

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2021-08-30
Est. Completion 2024-07-06
Pediatrix

28 total trials

What the finished NCT04971694 record still lists

NCT04971694 is an observational study that tracks outcomes without assigning an intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 1 intervention - of which No interventions or procedures is the first listed.

NCT04971694 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04971694 about?

NCT04971694 is a clinical study titled "Impact of Steroid, Diuretic, and Fluid Use on BPD Outcomes". Assess the impact of steroid, diuretic, and fluid practices on BPD outcomes in extreme premature infants in the Banner - University Medical Center Phoenix (BUMCP) neonatal intensive care unit (NICU).

What is the current status of trial NCT04971694?

This trial is currently completed. The enrollment target is 175 participants. The study started on 2021-08-30. Estimated completion is 2024-07-06.

What interventions are being tested in trial NCT04971694?

The interventions under investigation include: No interventions or procedures (OTHER).

Who is sponsoring clinical trial NCT04971694?

This trial is sponsored by Pediatrix, which has 28 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04722341 · 175 participants · NA

    Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

  • NCT05094037 · 175 participants · NA

    Orthotic Treatment of Diabetic Foot Ulcers

  • NCT05165745 · 175 participants · NA

    Stick2PrEP Cisgender Women and Trans Individuals

  • NCT05312255 · 175 participants · NA

    Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04971694, the US trial registry maintained by the National Library of Medicine. NCT04971694 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.